U.S. TPP vote may turn on biologics; China PE firm Lyfe raises $300M;

> One of Capitol Hill's biggest pharmaceutical advocates in the United States is raising objections to the Trans-Pacific Partnership and its language on drugs, because he is objecting to monopoly protections overseas on biologics and could threaten the pact's approval by Congress. Report

> Taiwan's TWi Pharmaceuticals named Rick Pallokat as the executive vice president of its U.S. subsidiary. TWi raised around $87 million via global depositary receipts in September that followed a management shake-up the previous month. Release

> U.S.-based orphan drugmaker Baxalta ($BXLT) said it has received approval from the U.S. FDA to make bulk Advate at its recombinant biologic manufacturing facility in Singapore for export to the U.S. market. Site manufacture of the product, a recombinant antihemophilic factor, was approved by the European Medicines Agency in January 2014. Release

> China-focused private equity firm Lyfe Capital raised nearly $300 million in a mix of dollars and yuan to invest in startup and early-stage healthcare companies, according to the China Money Network, citing a Chinese language announcement. Lyfe raised $210 million and RMB555 million with partners including U.S. and European pension funds, China Money Network said. Lyfe was started in the third quarter by James Zhao and Drake Yu. Report

> Chinese devicemaker Mindray Medical International ($MR) said third-quarter net revenues clocked in at $327.6 million, up 0.9%, as the firm is in the midst of a management-led buyout offer. Release

> A $60 million venture fund was launched by Medtronic ($MDT) and Sequoia Capital focused on China med tech startups in and outside the country, China Money Network reported, noting it has roped in development center Suzhou BioBay as a strategic partner. Report

> The Philippines FDA has warned of fake Clarithromycin antibiotic granules in circulation after receiving notice from registered product holder Abbott Laboratories ($ABT), the Inquirer newspaper reported. A fruit punch flavor manufactured in the United Kingdom is counterfeit, the newspaper said, citing the PFDA. Report

> China-focused Sinovac Biotech ($SVA) said third-quarter sales fell 2% to $16.8 million as it looks forward to a successful GMP inspection for production of its EV71 vaccine soon, the company said. Release

> San Diego-based HUYA Bioscience International has joined with TechCode Gu'an Life Sciences Park to work with firms in China on the development of innovative drugs that have global market potential. Release

> Japan's Astellas Pharma has named Peter Sandor as vice president and head of oncology therapeutic area for marketing strategy. He previously worked at Amgen ($AMGN) as vice president for Global Marketing and Therapeutic Area Head Oncology. Release

> India's Ministry of Health and Family Welfare said it is developing a mobile phone application that will help citizens locate and buy cheaper generic drugs. Report